Tg Therapeutics, Inc. TGTX
We take great care to ensure that the data presented and summarized in this overview for TG THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TGTX
View all-
Vanguard Group Inc Valley Forge, PA15.4MShares$495 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$367 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$293 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$115 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$103 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA2.57MShares$82.6 Million0.54% of portfolio
-
Goldman Sachs Group Inc New York, NY2.56MShares$82.3 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.53MShares$81.6 Million5.04% of portfolio
-
Opaleye Management Inc. Boston, MA2.28MShares$73.4 Million9.74% of portfolio
-
Morgan Stanley New York, NY2.16MShares$69.7 Million0.0% of portfolio
Latest Institutional Activity in TGTX
Top Purchases
Top Sells
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Insider Transactions at TGTX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 12
2024
|
Laurence N Charney Director |
SELL
Bona fide gift
|
Direct |
5,000
-2.35%
|
-
|
Nov 11
2024
|
Laurence N Charney Director |
SELL
Open market or private sale
|
Direct |
25,000
-10.53%
|
$750,000
$30.2 P/Share
|
Nov 11
2024
|
Sagar Lonial Director |
SELL
Open market or private sale
|
Direct |
5,000
-4.75%
|
$150,000
$30.44 P/Share
|
Nov 05
2024
|
Yann Echelard Director |
SELL
Open market or private sale
|
Direct |
20,000
-8.19%
|
$480,000
$24.48 P/Share
|
Jun 20
2024
|
Sagar Lonial Director |
SELL
Open market or private sale
|
Direct |
16,348
-13.45%
|
$261,568
$16.87 P/Share
|
Jun 19
2024
|
Yann Echelard Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+8.35%
|
-
|
Jun 19
2024
|
Kenneth Hoberman Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+7.75%
|
-
|
Jun 19
2024
|
Daniel Hume Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+8.47%
|
-
|
Jun 19
2024
|
Sagar Lonial Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+15.47%
|
-
|
Jun 19
2024
|
Laurence N Charney Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+8.57%
|
-
|
Jun 17
2024
|
Sagar Lonial Director |
SELL
Open market or private sale
|
Direct |
9,585
-8.8%
|
$153,360
$16.39 P/Share
|
Mar 13
2024
|
Sagar Lonial Director |
SELL
Open market or private sale
|
Direct |
5,000
-4.39%
|
$75,000
$15.94 P/Share
|
Mar 12
2024
|
Laurence N Charney Director |
SELL
Open market or private sale
|
Direct |
22,000
-9.27%
|
$330,000
$15.97 P/Share
|
Jan 06
2024
|
Michael S Weiss CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,001,908
+7.12%
|
-
|
Jan 05
2024
|
Laurence N Charney Director |
SELL
Open market or private sale
|
Direct |
17,500
-6.87%
|
$332,500
$19.03 P/Share
|
Jan 05
2024
|
Sean A Power CFO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+9.91%
|
-
|
Jan 03
2024
|
Sean A Power CFO |
SELL
Open market or private sale
|
Direct |
47,867
-7.31%
|
$765,872
$16.91 P/Share
|
Sep 28
2023
|
Yann Echelard Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+8.27%
|
-
|
Sep 28
2023
|
Daniel Hume Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+8.39%
|
-
|
Sep 28
2023
|
Laurence N Charney Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+7.28%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.19M shares |
---|
Bona fide gift | 5K shares |
---|---|
Open market or private sale | 168K shares |